Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

Core Viewpoint - Altai Capital Management has issued a letter to the OraSure Board, advocating for significant changes due to the company's chronic underperformance and proposing the appointment of their nominees to the Board [1][2]. Group 1: Underperformance Issues - OraSure's share price has significantly underperformed compared to similar companies and broader indices over the past five and ten years, primarily due to operational and strategic failures under current management [2]. - The company continues to incur cash losses while pursuing speculative diagnostics investments, negatively impacting shareholder value [2]. Group 2: Board Composition and Compensation - Independent directors own less than 1% of the company's shares but receive over $250,000 annually in compensation, indicating a lack of financial risk associated with their decisions [2]. - Over 90% of CEO Carrie Eglinton Manner's compensation is not linked to share price performance, with her earning approximately $15 million while shareholders have lost 60% of their investment since 2023 [2]. Group 3: Strategic Recommendations - A strategic review is necessary, including the potential sale of the entire business, to ensure the best returns for shareholders [2]. - Altai's nominees, Rishi Bajaj and John Bertrand, have proven track records in transforming companies and will align their compensation with shareholder returns [2].